Beyond Air
Garden City, United States · Biotechnology, Healthcare, Health Care
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neona
Key facts
- Headquarters
- Garden City, United States
- Employees
- 54
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (XAIR)
- Website
- beyondair.net
- Company page
Recent activity at Beyond Air
- : SEC 8-K (7.01): This filing reports a Regulation FD Disclosure by Beyond Air, Inc. dated October 8, 2026. The information includes a press release that the company believes is relevant for shareholders, although the company makes no admission regarding the materiality of the information shared. The report refers to Exhibit 99.1, which likely contains significant updates or announcements intended to inform investors while ensuring compliance with Regulation FD standards regarding material disclosures. No financial amounts or specific terms are mentioned in this filing.
- : SEC 8-K (5.02): On September 23, 2026, Beyond Air, Inc. (the 'Company') entered into an Employment Agreement with Robert Goodman, who has been serving as Chief Executive Officer since March 27, 2026. The agreement, effective immediately, stipulates that Mr. Goodman will receive an annual base salary of no less than $650,000, with potential annual bonuses that could range from 0% to 150% of his base salary based on performance. The agreement does not have a fixed term and provides specific terms for termination, including severance provisions in the event of a termination without cause or resignation for good reason. This appointment and agreement demonstrate the Company's commitment to its leadership and strategic direction.
- : SEC 8-K (7.01):
- : SEC 8-K (8.01): On August 6, 2026, Beyond Air, Inc. received a Compliance Letter from Nasdaq confirming that it regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), following a 1-for-20 reverse stock split on July 13, 2026. This compliance was achieved as the company's stock price remained above $1.00 per share for 17 consecutive trading days leading up to August 4, 2026. However, the Compliance Letter imposes a Discretionary Panel Monitor for one year, during which the company cannot submit a plan of compliance for any new deficiencies, placing its continued Nasdaq listing at risk if future compliance issues arise.
- : SEC 8-K (1.01): On July 29, 2026, Beyond Air, Inc. entered into a securities purchase agreement with various institutional investors and certain directors and executive officers. The agreement involves a private placement where the Company will sell 167,011 shares of common stock and various warrants (including Pre-Funded and Common Warrants) with a combined purchase price of $5.66 per share for institutional investors. This deal is expected to generate approximately $10.2 million in gross proceeds for the Company, which will be used for working capital and general corporate purposes. The Private Placement closing is anticipated on or about July 31, 2026, pending the satisfaction of customary closing conditions.
- : Beyond Air, Inc. secures up to $30.1 million in a private placement offering, led by institutional healthcare investors, to support the commercial launch of its second-generation LungFit PH.
- : SEC 8-K (7.01):
- : SEC 8-K (8.01):
- : SEC 8-K (8.01):
- : SEC 8-K (8.01):
Beyond Air funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Post-IPO Equity | $30.1M |
| Nov 2025 | Debt Financing | $32.0M |
| Oct 2024 | Venture | $20.6M |
| Jul 2024 | Venture | $128K |
| Jun 2023 | Seed | $1.4M |
Leadership
- Carey Robert, Director
- Bentsur Ron, Director
- Forbes William, Director
- Lee Yoori, Director
- Lucera Erick, Director
- Avniel Amir, Executive Officer, Director
- Steven Lisi, Executive Officer, Director
- Yoori Lee, Director
- Ari Raved, Director
- Erick Lucera, Director
- David Grossman, Director
- Ron Bentsur, Director
Verified email and direct lines for Beyond Air’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Beyond Air in the news
- Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance (Sep 02, 2026)
- Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH - BioSpace (Jun 16, 2025)
- Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing - Yahoo Finance (Jun 01, 2026)
- Beyond Air (Nasdaq:XAIR) - Stock Analysis - Simply Wall Street (Jul 17, 2019)
Companies similar to Beyond Air
- Omniscient Neurotechnology · Biotechnology, Healthcare, Health Care
- Enlaza Therapeutics · Biotechnology, Healthcare, Health Care
- Pharmazz · Biotechnology, Healthcare, Health Care
- Avalyn · Biotechnology, Healthcare, Health Care
- Shape Memory Medical · Biotechnology, Healthcare, Health Care
About Beyond Air: questions and answers
What does Beyond Air do?
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neona
Where is Beyond Air headquartered?
Beyond Air is headquartered in Garden City, United States.
How many employees does Beyond Air have?
Beyond Air has about 54 employees.
Has Beyond Air raised funding?
Yes. Fundz has recorded 5 funding events for Beyond Air. The most recent, Post-IPO Equity of $30.1M, was in Jul 2026.
What is the latest news on Beyond Air?
On Oct 08, 2026, SEC 8-K (7.01): This filing reports a Regulation FD Disclosure by Beyond Air, Inc. dated October 8, 2026. The information includes a press release that the company believes is relevant for shareholders, although the company makes no admission regarding the materiality of the information shared. The
Is Beyond Air a public company?
Yes. Beyond Air is publicly traded under the ticker XAIR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy